



# Tatva Chintan Pharma Chem Limited

(CIN:L24232GJ1996PLC029894)



Date: 28 April 2023

Ref No: TCPCL/SEC/2023-24/00006

**To,**  
**The General Manager,**  
**Corporate relationship department,**  
**BSE Limited**  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Fort,  
Mumbai-400 001

**The Manager,**  
**Listing department,**  
**National Stock Exchange of India Limited**  
Exchange Plaza, C-1, Block-G,  
Bandra-Kurla, Complex Bandra(E),  
Mumbai-400 051

**Scrip Code: 543321**

**Scrip Symbol: TATVA**

**Subject: Fund raising by issuance of debt securities by Large Corporates**

**Ref.: Chapter XII of Operational Circular No. SEBI/HO/DDHS/P/CIR/2021/613 dated August 10, 2021, as updated on April 13, 2022**

Dear Sir/Madam,

Pursuant to SEBI Operational Circular No. SEBI/HO/DDHS/P/CIR/2021/613 dated August 10, 2021, as updated on April 13, 2022, we hereby confirm that Tatva Chintan Pharma Chem Limited is not a Large Corporate as per the applicability criteria mentioned in clause 1.2 of Chapter XII of the above mentioned SEBI circular.

The details required as per the above circular are enclosed as Annexure - XII – A

We request you to kindly take the same on record.

Thanking You,

Your Faithfully,  
**For Tatva Chintan Pharma Chem Limited**

**Ishwar Nayi**  
**Company Secretary and Compliance Officer**  
**M. No.: A37444**

Enclosed: As above

**Annexure - XII – A**

**Format of the Initial Disclosure to be made by an entity identified as a Large Corporate**

(To be submitted to the Stock Exchange(s) within 30 days from the beginning of the FY)

Sr. No.	Particulars	Details
1.	Name of the Company	<b>TATVA CHINTAN PHARMA CHEM LIMITED</b>
2.	CIN	<b>L24232GJ1996PLC029894</b>
3.	Outstanding borrowing of company as on 31 March 2023, as applicable (in Rs. crore)	<b>Rs. 14.05 Crores</b>
4.	Highest Credit Rating During the previous FY along with name of the Credit Rating Agency	<b>CRISIL A-/Stable (Long Term Rating)</b> <b>CRISIL A2+ (Short Term Rating)</b>
		<b>Agency – CRISIL Ratings Limited</b>
5.	Name of stock exchange* in which the fine shall be paid, in case of shortfall in the required borrowing under the framework	<b>Not Applicable</b>

We confirm that **we are not a Large Corporate** as per the applicability criteria given under the Chapter XII of SEBI Operational circular dated August 10, 2021, as amended.

**For Tatva Chintan Pharma Chem Limited**

\_\_\_\_\_  
**Ishwar Nayi**  
**Company Secretary**  
**Membership No.: A37444**  
Tel: +91 75748 48533  
E-mail: cs@tatvachintan.com

\_\_\_\_\_  
**Ashok Bothra**  
**Chief Financial Officer**  
Tel: +91 75748 48533  
E-mail: finance@tatvachintan.com

Date – 28/04/2023

\*Note: In terms paragraph of 2.2(d) of the circular, beginning FY2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.